Viewing 1 to 10 out of 31 studies
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
CONDITIONS
Lung Cancer
DESCRIPTION
The purpose of this study is to compare overall survival (OS) and progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR). Hypothesis (H1): Concurrent chemoradiation therapy with pembrolizumab followed by pembrolizumab plus olaparib is superior to concurrent chemoradiation therapy alone with respect to PFS per RECIST 1.1 by BICR. Hypothesis (H2): Concurrent chemoradiation therapy with pembrolizumab followed by pembrolizumab is superior to concurrent chemoradiation therapy alone with respect to PFS per RECIST 1.1 by BICR. Hypothesis (H3): Concurrent chemoradiation therapy with pembrolizumab followed by pembrolizumab plus olaparib is superior to concurrent chemoradiation therapy alone with respect to OS. Hypothesis (H4): Concurrent chemoradiation therapy with pembrolizumab followed by pembrolizumab is superior to concurrent chemoradiation therapy alone with respect to OS.
LOCATIONS
University of Kentucky Chandler Medical Center ( Site 0138) - Lexington, Kentucky
A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma
CONDITIONS
Brain Cancer
DESCRIPTION
This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with low-grade glioma (a common type of brain cancer) that has come back after prior treatment (recurrent) or does not respond to therapy (progressive). Selumetinib is a drug that works by blocking a protein that lets tumor cells grow without stopping. Vinblastine blocks cell growth by stopping cell division and may kill cancer cells. Giving selumetinib in combination with vinblastine may work better than selumetinib alone in treating recurrent or progressive low-grade glioma.
LOCATIONS
Norton Children's Hospital - Louisville, Kentucky
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
CONDITIONS
Prostate Cancer
DESCRIPTION
This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease.
LOCATIONS
Exelixis Clinical Site #243 - Louisville, Kentucky
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
CONDITIONS
Breast Cancer
DESCRIPTION
This phase II trial studies how well FDG-PET/CT works in assessing the response of patients with breast cancer that has spread to the bones or mostly to the bones (bone-dominant metastatic breast cancer). Diagnostic procedures, such as FDG-PET/CT, may work better in measuring breast cancer activity before and after treatment compared to other standard imaging tests.
LOCATIONS
Jewish Hospital - Louisville, Kentucky
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
CONDITIONS
Multiple Myeloma/Amyloidosis
DESCRIPTION
The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS).
LOCATIONS
University of Kentucky - Lexington, Kentucky
Norton Cancer Institute - Louisville, Kentucky
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
CONDITIONS
Breast Cancer
DESCRIPTION
This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). In this study, all participants will get either tucatinib or placebo. Participants will be assigned randomly to a group. This is a blinded study, so patients and their doctors will not know which group a participant is in. All participants will also get trastuzumab and pertuzumab. These are 2 drugs used to treat this type of cancer.
LOCATIONS
Norton Cancer Institute - Louisville, Kentucky
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
CONDITIONS
Breast Cancer
DESCRIPTION
This phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases). Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan may shrink the cancer in the brain and/or extend the time until the cancer gets worse.
LOCATIONS
Flaget Memorial Hospital - Bardstown, Kentucky
Commonwealth Cancer Center-Corbin - Corbin, Kentucky
Saint Joseph Radiation Oncology Resource Center - Lexington, Kentucky
Saint Joseph Hospital East - Lexington, Kentucky
Saint Joseph London - London, Kentucky
Jewish Hospital - Louisville, Kentucky
Saints Mary and Elizabeth Hospital - Louisville, Kentucky
UofL Health Medical Center Northeast - Louisville, Kentucky
Jewish Hospital Medical Center South - Shepherdsville, Kentucky
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
CONDITIONS
Lung Cancer
DESCRIPTION
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
LOCATIONS
King's Daughter's Medical Center - Ashland, Kentucky
Flaget Memorial Hospital - Bardstown, Kentucky
Commonwealth Cancer Center-Corbin - Corbin, Kentucky
Baptist Health Hardin - Elizabethtown, Kentucky
Saint Joseph Radiation Oncology Resource Center - Lexington, Kentucky
Saint Joseph Hospital East - Lexington, Kentucky
University of Kentucky/Markey Cancer Center - Lexington, Kentucky
Saint Joseph London - London, Kentucky
Jewish Hospital - Louisville, Kentucky
Baptist Health Louisville - Louisville, Kentucky
Saints Mary and Elizabeth Hospital - Louisville, Kentucky
Jewish Hospital Medical Center Northeast - Louisville, Kentucky
Saint Claire Regional Medical Center - Morehead, Kentucky
Owensboro Health Mitchell Memorial Cancer Center - Owensboro, Kentucky
Jewish Hospital Medical Center South - Shepherdsville, Kentucky
A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy
CONDITIONS
Brain Cancer
DESCRIPTION
This protocol is for a lead-in safety study of 5 patients followed by a randomized Phase 2 clinical trial of BMX-001, a new class of pharmaceutical, in 64 patients with multiple brain metastases (MBM) undergoing whole brain radiation therapy (WBRT). Preliminary studies have demonstrated that BMX-001 provides protection of normal tissues from radiation-induced injury and augments tumor growth inhibition.
LOCATIONS
University of Kentucky - Lexington, Kentucky
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors
CONDITIONS
Other
DESCRIPTION
This clinical trial studies cancer survivors to identify those who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. A patient's genes may affect the risk of developing complications, such as congestive heart failure, avascular necrosis, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications.
LOCATIONS
University of Kentucky/Markey Cancer Center - Lexington, Kentucky
Norton Children's Hospital - Louisville, Kentucky

To top